Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

Impact · against what's priced in

ADXN receives a modest positive catalyst as its spin-out Neurosterix clears Phase 1, creating a path to Phase 2 valuation. The impact is tempered by Addex's limited 20% equity stake and the fact that the update provides progress rather than definitive proof of efficacy.

ADXN+0.30: No priced-in read yet
In context: The completion of Phase 1 studies for NTX-253 and the plan to move into Phase 2 creates a new clinical milestone for a program where Addex holds a 20% stake.
Read from the article alone

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

pharmaceuticals
biotech
ADXN
SCHA
clinical trials
drug development
phase 1
phase 2
schizophrenia
spin out

Search tags

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Track these names every morning.

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Track these names every morning.

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY